Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1

Background: Although nitisinone is successfully used to treat hereditary tyrosinemia type 1 (HT-1) with the recommended twice-daily dosing, data describing a long half-life motivate less frequent dosing. Therefore, in agreement with the Pharmacovigilance Risk Assessment Committee at the European Med...

Descripción completa

Detalles Bibliográficos
Autores principales: Guffon, Nathalie, Bröijersén, Anders, Palmgren, Ingrid, Rudebeck, Mattias, Olsson, Birgitta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874213/
https://www.ncbi.nlm.nih.gov/pubmed/28643275
http://dx.doi.org/10.1007/8904_2017_29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874213/
https://www.ncbi.nlm.nih.gov/pubmed/28643275
http://dx.doi.org/10.1007/8904_2017_29

Ejemplares similares